Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.
Mark Bagnall
Advertisement
Mark Bagnall is CEO of Phenomix.
Articles by Mark Bagnall
Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.
GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.
Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
2
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
3
What Unexpected Costs do GLP-1 Patients Face?
4
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
5